NICE, the health technology assessment body for England and Wales, has issued a new draft guideline that recommends against using cannabis-based medicines to treat chronic pain because they are of only “modest” efficacy in this indication.
It says that GW Pharmaceuticals’ Sativex (cannabidiol spray) should not be used for treating spasticity in multiple sclerosis because it...








